Drug discovery is a complex and multidisciplinary process aimed at identifying new medicines to treat diseases, driven by advances in biotechnology and computational methods. To address the challenges associated with the use of anti-inflammatory drugs in adolescent sports, we have developed a novel approach leveraging graph convolutional networks (GCN) for drug discovery. Our GCN-based method, named GCN-Med, integrates diverse data sources, including molecular structures, biological activity profiles, and known side-effect information, to predict new drug candidates with reduced side effects. Through the construction of a comprehensive dataset and careful tuning of the training parameters, we observed a significant improvement in the model's ability to accurately predict the side effects of anti-inflammatory drugs, as evidenced by decreasing Mean Absolute Error (MAE) and Mean Squared Error (MSE) over the course of training. Comparative analysis with alternative models, such as Random Forest and traditional Graph Neural Networks (GNNs), further highlighted the superiority of GCN-Med in capturing the complex relationships within the drug discovery dataset. Visualizations of the predicted versus actual side effect values for ten drugs also confirmed the robustness of GCN-Med in forecasting the side effects of anti-inflammatory drugs. This GCN-based approach offers a promising avenue for developing safer and more effective treatment options to maintain athletic performance while reducing the side effects of anti-inflammatory drugs in adolescent sports.

Xinyu Liang. A GCN-based drug discovery approach to reduce the side effects of anti-inflammatory drugs in adolescent sports and maintain athletic performance. Academic Journal of Medicine & Health Sciences (2025), Vol. 6, Issue 2: 65-73. https://doi.org/10.25236/AJMHS.2025.060210.

[1] Acharjee, Animesh, et al.(2020). A random forest based biomarker discovery and power analysis framework for diagnostics research. BMC medical genomics, 13: 1-14.

[2] Dhudum, Rushikesh, Ankit Ganeshpurkar, and Atmaram Pawar(2024). Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. Drugs and Drug Candidates, 3.1: 148-171.

[3] Oprea, T. I., Mestres, J., & Enrich, C. (2019). The impact of machine learning in drug discovery. Nature Reviews Drug Discovery, 18(4), 251-267.

[4] Zhu, H., Xie, Q., & Chen, X. (2018). Machine learning-based prediction of ADME/T properties: a review. Journal of Pharmaceutical Sciences, 107(3), 693-708.

[5] Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8-17.

[6] Harrer, T., Ratzan, S., & Madigan, D. (2019). Deep learning for adverse event prediction using electronic health records. Journal of the American Medical Informatics Association, 26(1), 10-18. 

[7] Wu, Felix, et al.(2019). Simplifying graph convolutional networks. International conference on machine learning. PMLR.

[8] Veličković, Petar, et al.(2017). Graph attention networks. arXiv preprint arXiv:1710.10903.

[9] Wu, Zonghan, et al.(2020). A comprehensive survey on graph neural networks. IEEE transactions on neural networks and learning systems, 32.1: 4-24.

[10] Sanders, Jason, and Edward Kandrot (2010). CUDA by example: an introduction to general-purpose GPU programming. Addison-Wesley Professional.